Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Opicapone: A Review in Parkinson’s Disease
Lesley J. Scott
CNS Drugs (2021) Vol. 35, Iss. 1, pp. 121-131
Closed Access | Times Cited: 21

Showing 21 citing articles:

Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
Peter Jenner, José‐Francisco Rocha, Joaquim J. Ferreira, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 9, pp. 1019-1033
Open Access | Times Cited: 29
A decade of pyridine containing heterocycles in the approved USFDA drugs: A medicinal chemistry-based analysis
Ashish Ranjan Dwivedi, Shivani Jaiswal, Deepak Kukkar, et al.
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 4
Opicapone

Cambridge University Press eBooks (2025), pp. 324-332
Closed Access
Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
Javed Ahmad, Nafis Haider, Mohammad Ahmed Khan, et al.
Biochemical Pharmacology (2021) Vol. 195, pp. 114849-114849
Closed Access | Times Cited: 17
Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
Diego Santos‐García, Gustavo Fernández‐Pajarín, Juan Manuel Oropesa-Ruiz, et al.
Brain Sciences (2022) Vol. 12, Iss. 3, pp. 383-383
Open Access | Times Cited: 9
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
Gizem Kaykı-Mutlu, Martin C. Michel
Naunyn-Schmiedeberg s Archives of Pharmacology (2021) Vol. 394, Iss. 5, pp. 839-852
Open Access | Times Cited: 11
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
Valentina Leta, Daniel J. van Wamelen, Federico Aureli, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 7, pp. 925-930
Open Access | Times Cited: 4
Developmental and behavioral toxicity assessment of opicapone in zebrafish embryos
Zhengkang Su, Kaiyu Guan, Yunbin Liu, et al.
Ecotoxicology and Environmental Safety (2022) Vol. 249, pp. 114340-114340
Open Access | Times Cited: 7
Opicapone in Uk Clinical Practice: effectiveness, Safety and Cost Analysis in Patients With Parkinson’s Disease
Christine Schofield, К. Ray Chaudhuri, Camille Carroll, et al.
Neurodegenerative Disease Management (2022) Vol. 12, Iss. 2, pp. 77-91
Open Access | Times Cited: 5
A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates
Vinod Metta, Huzaifa Ibrahim, Neha Muralidharan, et al.
Journal of Neural Transmission (2023) Vol. 131, Iss. 1, pp. 25-30
Open Access | Times Cited: 2
Imidazole hydrochloride promoted synthesis of 3,5-disubstituted-1,2,4-oxadiazoles
Xuetong Wang, Yin Wang, Xiao‐Ling Liu, et al.
Tetrahedron (2021) Vol. 100, pp. 132496-132496
Closed Access | Times Cited: 4
Recent Advancements in Parkinson\'s Disease
Sahil Mehta
Journal of Postgraduate Medicine Education and Research (2024) Vol. 58, Iss. 1, pp. 1-2
Open Access
Most Potential Neuroprotective compound isolated from Allium sativum Targeting Alpha Synuclein involved in Parkinson’s Disease identified through Molecular Docking and MTT Assay
S Rehan Ahmad, Md. Zeyaullah, Abdullah M. AlShahrani, et al.
Research Square (Research Square) (2024)
Closed Access
Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Matthias Höllerhage, Jos S. Becktepe, Joseph Claßen, et al.
Journal of Neurology (2024) Vol. 271, Iss. 11, pp. 7071-7101
Open Access
Management of OFF condition in Parkinson disease
Jessa Koch
Mental Health Clinician (2023) Vol. 13, Iss. 6, pp. 289-297
Open Access | Times Cited: 1
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson’s Disease Patients with Motor Fluctuations
Heinz Reichmann, Karla Eggert, Christian Oehlwein, et al.
European Neurology (2022) Vol. 85, Iss. 5, pp. 389-397
Open Access | Times Cited: 2
Opicapone Protects Against Hyperhomocysteinemia-Induced Increase in Blood–Brain Barrier Permeability
Jian Wang, Bo Zheng, Shu Yang, et al.
Neurotoxicity Research (2021) Vol. 39, Iss. 6, pp. 2018-2028
Closed Access | Times Cited: 1
Radiolabeling fingolimod with technetium-99 m and evaluating its biological affinity by in vitro method
Emre Uygur, Yasemın Parlak, Kadriye Büşra Karatay, et al.
Journal of Radioanalytical and Nuclear Chemistry (2023) Vol. 332, Iss. 11, pp. 4781-4789
Closed Access
A review on the current status and development of Parkinson's clinical drugs
Yuxin Huang
(2023), pp. 45-45
Closed Access
Catechol-O-methyltransferase (COMT)
Giusy Tassone, Simone Carradori, Samuele Maramai, et al.
Elsevier eBooks (2023), pp. 63-81
Closed Access
Unveiling the Hidden Challenges: Non-Motor Disorders in Parkinson’s Disease
Francisco Nieto-Escámez, Esteban Obrero‐Gaitán, Héctor García‐López, et al.
Brain Sciences (2023) Vol. 13, Iss. 12, pp. 1710-1710
Open Access
Page 1

Scroll to top